Specific modulation of protein kinase activity via small peptides

Regulatory Peptides

Volumn 153, Issue 1-3, 2009, Pages 11-18

  Costa Junior, Helio Miranda ^a   Suetsugu, Mariana J ^a   Krieger, José Eduardo ^a   Schechtman, Deborah ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Kinases; Peptide modulators; Protein protein interaction; Signaling

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DOCKING PROTEIN; IMATINIB; ISOPRENALINE; PEPTIDE; PROSTAGLANDIN E1; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PSEUDOPEPTIDE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

DRUG BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; BINDING SITES; COMPUTATIONAL BIOLOGY; PEPTIDES; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 59849109241     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.12.002     Document Type: Review

References (82)

1. Schechtman D., and Mochly-Rosen D. Isozyme-specific inhibitors and activators of protein kinase C. Methods Enzymol 345 (2002) 470-489
2. Inagaki K., Chen L., Ikeno F., Lee F.H., Imahashi K., Bouley D.M., Rezaee M., Yock P.G., Murphy E., and Mochly-Rosen D. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 108 19 (2003) 2304-2307
3. Torchilin V.P., and Lukyanov A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8 6 (2003) 259-266
4. Dietz G.P., and Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 27 2 (2004) 85-131
5. Kaidanovich-Beilin O., and Eldar-Finkelman H. Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda) 21 (2006) 411-418
6. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269 14 (1994) 10444-10450
7. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., and Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271 30 (1996) 18188-18193
8. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., Becker-Hapak M., Ezhevsky S.A., and Dowdy S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4 12 (1998) 1449-1452
9. Chen L., Wright L.R., Chen C.H., Oliver S.F., Wender P.A., and Mochly-Rosen D. Molecular transporters for peptides: delivery of a cardioprotective epsilon PKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem Biol 8 12 (2001) 1123-1129
10. Oess S., and Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther 7 9 (2000) 750-758
11. Dokka S., Toledo-Velasquez D., Shi X., Wang L., and Rojanasakul Y. Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm Res 14 12 (1997) 1759-1764
12. Pooga M., Hallbrink M., Zorko M., and Langel U. Cell penetration by transportan. Faseb J 12 1 (1998) 67-77
13. Elliott G., and O'Hare P. Intercellular trafficking and protein delivery by a herpes virus structural protein. Cell 88 2 (1997) 223-233
14. Pontiroli A.E., Pajetta E., Calderara A., Alberetto M., Pozza G., Manganelli V., Resmini G., Tessari L., and Maresca V. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study. J Endocrinol Investig 14 1 (1991) 47-51
15. Gomez-Cabrero A., Comes N., Gonzalez-Linares J., de Lapuente J., Borras M., Pales J., Gual A., Gasull X., and Morales M. Use of transduction proteins to target trabecular meshwork cells: outflow modulation by profilin I. Mol Vis 11 (2005) 1071-1082
16. Johansson H.J., El-Andaloussi S., Holm T., Mae M., Janes J., Maimets T., and Langel U. Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol Ther 16 1 (2008) 115-123
17. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J Control Release 109 1-3 (2005) 77-85
18. Schechtman D., and Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 20 44 (2001) 6339-6347
19. Ubersax J.A., and Ferrell Jr. J.E. Mechanisms of specificity in protein phosphorylation. Nat Rev, Mol Cell Biol 8 7 (2007) 530-541
20. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., and Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 15 (2002) 4236-4243
21. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1 7 (2002) 493-502
22. Levitt M.L., and Koty P.P. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 17 3 (1999) 213-226
23. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 5486 (2000) 1938-1942
24. Williams D.H., and Mitchell T. Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr Opin Pharmacol 2 5 (2002) 567-573
25. Yang J., Cron P., Thompson V., Good V.M., Hess D., Hemmings B.A., and Barford D. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9 6 (2002) 1227-1240
26. Maller J.L., Kemp B.E., and Krebs E.G. In vivo phosphorylation of a synthetic peptide substrate of cyclic AMP-dependent protein kinase. Proc Natl Acad Sci U S A 75 1 (1978) 248-251
27. Zaccolo M., De Giorgi F., Cho C.Y., Feng L., Knapp T., Negulescu P.A., Taylor S.S., Tsien R.Y., and Pozzan T. A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol 2 1 (2000) 25-29
28. Zhang J., Ma Y., Taylor S.S., and Tsien R.Y. Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering. Proc Natl Acad Sci U S A 98 26 (2001) 14997-15002
29. Ting A.Y., Kain K.H., Klemke R.L., and Tsien R.Y. Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc Natl Acad Sci U S A 98 26 (2001) 15003-15008
30. Kunkel M.T., Ni Q., Tsien R.Y., Zhang J., and Newton A.C. Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. J Biol Chem 280 7 (2005) 5581-5587
31. Violin J.D., Zhang J., Tsien R.Y., and Newton A.C. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. J Cell Biol 161 5 (2003) 899-909
32. Scott J.D., Fischer E.H., Demaille J.G., and Krebs E.G. Identification of an inhibitory region of the heat-stable protein inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 82 13 (1985) 4379-4383
33. Tsigelny I., Grant B.D., Taylor S.S., and Ten Eyck L.F. Catalytic subunit of cAMP-dependent protein kinase: electrostatic features and peptide recognition. Biopolymers 39 3 (1996) 353-365
34. Li Y., van Kerkhof P., Marzolo M.P., Strous G.J., and Bu G. Identification of a major cyclic AMP-dependent protein kinase A phosphorylation site within the cytoplasmic tail of the low-density lipoprotein receptor-related protein: implication for receptor-mediated endocytosis. Mol Cell Biol 21 4 (2001) 1185-1195
35. Ilouz R., Kowalsman N., Eisenstein M., and Eldar-Finkelman H. Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. J Biol Chem 281 41 (2006) 30621-30630
36. Kaidanovich-Beilin O., and Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther 316 1 (2006) 17-24
37. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334 6184 (1988) 661-665
38. Pearson R.B., Wettenhall R.E., Means A.R., Hartshorne D.J., and Kemp B.E. Autoregulation of enzymes by pseudosubstrate prototopes: myosin light chain kinase. Science 241 4868 (1988) 970-973
39. Kemp B.E., Pearson R.B., House C., Robinson P.J., and Means A.R. Regulation of protein kinases by pseudosubstrate prototopes. Cell Signal 1 4 (1989) 303-311
40. House C., Robinson P.J., and Kemp B.E. A synthetic peptide analog of the putative substrate-binding motif activates protein kinase C. FEBS Lett 249 2 (1989) 243-247
41. Makowske M., and Rosen O.M. Complete activation of protein kinase C by an antipeptide antibody directed against the pseudosubstrate prototope. J Biol Chem 264 27 (1989) 16155-16159
42. Johnson J.A. Differential inhibition by alpha and epsilon PKC pseudosubstrate sequences: a putative mechanism for preferential PKC activation in neonatal cardiac myocytes. Life Sci 74 25 (2004) 3153-3172
43. Craig A., Scott M., Burch L., Smith G., Ball K., and Hupp T. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep 4 8 (2003) 787-792
44. Xu B., Wilsbacher J.L., Collisson T., and Cobb M.H. The N-terminal ERK-binding site of MEK1 is required for efficient feedback phosphorylation by ERK2 in vitro and ERK activation in vivo. J Biol Chem 274 48 (1999) 34029-34035
45. Bardwell A.J., Flatauer L.J., Matsukuma K., Thorner J., and Bardwell L. A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission. J Biol Chem 276 13 (2001) 10374-10386
46. Enslen H., Brancho D.M., and Davis R.J. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. Embo J 19 6 (2000) 1301-1311
47. Ho D.T., Bardwell A.J., Abdollahi M., and Bardwell L. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem 278 35 (2003) 32662-32672
48. Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P., Currie R., Downes C.P., and Alessi D.R. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 9 8 (1999) 393-404
49. Balendran A., Currie R., Armstrong C.G., Avruch J., and Alessi D.R. Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 274 52 (1999) 37400-37406
50. Ferguson M., Luciani M.G., Finlan L., Rankin E.M., Ibbotson S., Fersht A., and Hupp T.R. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death. Cell Cycle 3 1 (2004) 80-89
51. Niv M.Y., Rubin H., Cohen J., Tsirulnikov L., Licht T., Peretzman-Shemer A., Cna'an E., Tartakovsky A., Stein I., Albeck S., Weinstein I., Goldenberg-Furmanov M., Tobi D., Cohen E., Laster M., Ben-Sasson S.A., and Reuveni H. Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J Biol Chem 279 2 (2004) 1242-1255
52. Saldanha S.A., Kaler G., Cottam H.B., Abagyan R., and Taylor S.S. Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. Anal Chem 78 24 (2006) 8265-8272
53. Souza G.R., Christianson D.R., Staquicini F.I., Ozawa M.G., Snyder E.Y., Sidman R.L., Miller J.H., Arap W., and Pasqualini R. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc Natl Acad Sci U S A 103 5 (2006) 1215-1220
54. Barbas III C.F. Recent advances in phage display. Curr Opin Biotechnol 4 5 (1993) 526-530
55. Rader C., and Barbas III C.F. Phage display of combinatorial antibody libraries. Curr Opin Biotechnol 8 4 (1997) 503-508
56. Mochly-Rosen D., Khaner H., Lopez J., and Smith B.L. Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme. J Biol Chem 266 23 (1991) 14866-14868
57. Stebbins E.G., and Mochly-Rosen D. Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C. J Biol Chem 276 32 (2001) 29644-29650
58. Csukai M., Chen C.H., De Matteis M.A., and Mochly-Rosen D. The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon. J Biol Chem 272 46 (1997) 29200-29206
59. Mochly-Rosen D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science 268 5208 (1995) 247-251
60. Ron D., and Mochly-Rosen D. An autoregulatory region in protein kinase C: the pseudoanchoring site. Proc Natl Acad Sci U S A 92 2 (1995) 492-496
61. Schechtman D., Craske M.L., Kheifets V., Meyer T., Schechtman J., and Mochly-Rosen D. A critical intramolecular interaction for protein kinase Cepsilon translocation. J Biol Chem 279 16 (2004) 15831-15840
62. Liron T., Chen L.E., Khaner H., Vallentin A., and Mochly-Rosen D. Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide. J Mol Cell Cardiol 42 4 (2007) 835-841
63. Kheifets V., Bright R., Inagaki K., Schechtman D., and Mochly-Rosen D. Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function. J Biol Chem 281 32 (2006) 23218-23226
64. Murriel C.L., Churchill E., Inagaki K., Szweda L.I., and Mochly-Rosen D. Protein kinase C delta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J Biol Chem 279 46 (2004) 47985-47991
65. Bright R., Raval A.P., Dembner J.M., Perez-Pinzon M.A., Steinberg G.K., Yenari M.A., and Mochly-Rosen D. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci 24 31 (2004) 6880-6888
66. Chen L., Hahn H., Wu G., Chen C.H., Liron T., Schechtman D., Cavallaro G., Banci L., Guo Y., Bolli R., Dorn II G.W., and Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A 98 20 (2001) 11114-11119
67. Chen C.H., Gray M.O., and Mochly-Rosen D. Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: role of epsilon protein kinase C. Proc Natl Acad Sci U S A 96 22 (1999) 12784-12789
68. Kheifets V., and Mochly-Rosen D. Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. Pharmacol Res 55 6 (2007) 467-476
69. Hundsrucker C., Rosenthal W., and Klussmann E. Peptides for disruption of PKA anchoring. Biochem Soc Trans 34 4 (2006) 472-473
70. McConnachie G., Langeberg L.K., and Scott J.D. AKAP signaling complexes: getting to the heart of the matter. Trends Mol Med 12 7 (2006) 317-323
71. Newlon M.G., Roy M., Morikis D., Carr D.W., Westphal R., Scott J.D., and Jennings P.A. A novel mechanism of PKA anchoring revealed by solution structures of anchoring complexes. Embo J 20 7 (2001) 1651-1662
72. Carr D.W., Hausken Z.E., Fraser I.D., Stofko-Hahn R.E., and Scott J.D. Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain. J Biol Chem 267 19 (1992) 13376-13382
73. Hausken Z.E., Dell'Acqua M.L., Coghlan V.M., and Scott J.D. Mutational analysis of the A-kinase anchoring protein (AKAP)-binding site on RII. Classification Of side chain determinants for anchoring and isoform selective association with AKAPs. J Biol Chem 271 46 (1996) 29016-29022
74. Taylor S.S., Kim C., Cheng C.Y., Brown S.H., Wu J., and Kannan N. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. Biochim Biophys Acta 1784 1 (2008) 16-26
75. Alto N.M., Soderling S.H., Hoshi N., Langeberg L.K., Fayos R., Jennings P.A., and Scott J.D. Bioinformatics design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring. Proc Natl Acad Sci U S A 100 8 (2003) 4445-4450
76. Kammerer S., Burns-Hamuro L.L., Ma Y., Hamon S.C., Canaves J.M., Shi M.M., Nelson M.R., Sing C.F., Cantor C.R., Taylor S.S., and Braun A. Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci U S A 100 7 (2003) 4066-4071
77. Bonny C., Oberson A., Negri S., Sauser C., and Schorderet D.F. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50 1 (2001) 77-82
78. Chu L., and Robinson D.K. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 12 2 (2001) 180-187
79. Eldridge G.R., Vervoort H.C., Lee C.M., Cremin P.A., Williams C.T., Hart S.M., Goering M.G., O'Neil-Johnson M., and Zeng L. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal Chem 74 16 (2002) 3963-3971
80. Bain J., Plater L., Elliott M., Shapiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 3 (2007) 297-315
81. Hastings I.M. Modeling parasite drug resistance: lessons for management and control strategies. Trop Med Int Health 6 11 (2001) 883-890
82. Bates E., Bode C., Costa M., Gibson C.M., Granger C., Green C., Grimes K., Harrington R., Huber K., Kleiman N., Mochly-Rosen D., Roe M., Sadowski Z., Solomon S., and Widimsky P. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117 7 (2008) 886-896